Gastrointestinal Oncology
Milano
Via Giacomo Venezian, 1 , 20133 Milano MI

The Gastrointestinal Oncology Unit specializes in the diagnosis and medical treatment of tumors affecting the stomach and esophagus, small intestine, colon-rectum and anus, pancreas, biliary tract, appendix (including the clinical syndrome pseudomyxoma peritonei), as well as abdominal, thoracic, and cutaneous neuroendocrine tumors (including Merkel cell carcinoma).
Given their complexity, gastrointestinal tract neoplasms in our institution are managed through a diagnostic and therapeutic approach shared among multiple specialists from the very first patient visit. In collaboration with surgeons, gastroenterology endoscopists, radiologists, nutritionists, radiation therapists, palliative care physicians, and pathologists, a multidisciplinary treatment plan is developed. This multidisciplinary treatment plan ensures optimal timing and coordination of interventions and diagnostic procedures. Additionally, our Unit emphasizes the importance of patient comprehension of the disease and adjusts care, where feasible, to address individual needs, with careful consideration of communication and psychological factors. We are also engaged in research focused on minimizing potential disparities in access to care.
Each patient receives a cutting-edge care plan, and clinical research often allows us to offer innovative treatments such as those targeting genetic characteristics, immunotherapy, or novel treatment mechanisms.
Our team is deeply committed to designing and conducting academic clinical studies to improve practice and therapeutic strategies for gastrointestinal tumors. Some of our staff members hold significant positions in professional associations and scientific networks, such as the GONO Foundation, known for developing treatments recommended in international guidelines.
Our research has contributed to defining current treatment standards for gastrointestinal cancers, including colorectal and gastroesophageal carcinomas.
Finally, we actively participate in drafting national and international guidelines for the treatment of gastrointestinal tumors, serving as a global reference for clinical and scientific activities. Our team meets regularly to ensure synergy among different professionals (physicians, research nurses, study coordinators), maintain continuous scientific updates, and uphold consistency in therapeutic strategy formulation.
First SSN examinations can be booked through the same channels as other specialist services:
- switchboard INT: (+39) 02.2390 1.
- in person (CUP AMBULATORY GENERAL)
To have access to the first examination you need a ‘First oncological examination’ referral, issued by your general practitioner or other specialist, stating the diagnosis or suspected diagnosis.
Visits conducted through the National Health System necessarily require the presence of the patient
- Colorectal carcinoma
- Carcinomas of the stomach, gastroesophageal junction and oesophagus
- Carcinoma of the pancreas
- Carcinoma of the biliary tract
- Neuroendocrine tumours
- Mail: filippo.pietrantonio@istitutotumori.mi.it
- Mail: renata.spallone@istitutotumori.mi.it
- Tel: 0223903822
Fax: 0223902149
Access hours for medical representatives: by appointment to be agreed
Dott. Pietrantonio Filippo
Head
Dott.ssa Fazio Roberta
Doctor
Dott. Manca Paolo
Dott.ssa Morano Federica
Doctor
Dott.ssa Niger Monica
Doctor
Dott.ssa Pircher Chiara Carlotta
Doctor
Dott. PhD Prisciandaro Michele
Doctor
Dott.ssa Raimondi Alessandra
Doctor
Dott. Randon Giovanni
Doctor
Specializzandi tesisti
- Filippo Ghelardi
- Alberto Giovanni Leone
- Vincenzo Nasca
- Simone Oldani
Infermiere di ricerca
- Sara Alessandrini
- Eleonora Cristarella
Study coordinator
- Maria Francesca Bosco
- Anna Chiaramonte
- Salsabil Mohamed
- Federica Palermo
- Michele Palazzo
- Viola Puddinu
- Alessandro Salamone
Segreteria
- Renata Spallone
Actioning the resistance mechanisms to different antibody-drug conjugates in gastric cancer
AI-Driven Optimization for Predicting Clinico-Pathological Parameters from CT Scans in Locally Advanced Colon Cancer (LACC)
Change Promoting: Temozolomide and irinotecan regimen as liquid biopsy-guided non-cross resistant sequential adjuvant treatment of patients with MGMT methylated, microsatellite stable colorectal cancer failing to achieve seroreversion after a standard
Exploiting Liquid Biopsy To Predict Outcomes And Progression Patterns In Ras Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) Patients Randomized To Either 5-Fu/Lv Plus Panitumumab Or Panitumumab Alone As Maintenance Strategy Following Folfox Plus Panit
Molecular profiling of HER2 positive metastatic gastric cancer patients with exceptional response to trastuzumab-based therapy
Moving forward from single-agent trastuzumab thanks to a reverse translational approach in HER2+ advanced gastric cancer
Window-of-opportunity umbrella trial as a translational platform for short-course pre-operative targeted treatments in non-metastatic resectable colorectal cancer: the UNICORN study
Last update: 16/07/2025